Payment overview · 2025
General Payments
$2,035.69
100 reported records · 14 companies
Healthcare provider profile · identity verified
Eric Eugene Drolshagen, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT SMITH, AR · NPI 1598285181
Verified facts
What the public records show
CMS Open Payments records show Eric Eugene Drolshagen, MD received $2,035.69 in general payments during 2025 across 100 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $748.56 | 36.8% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $327.29 | 16.1% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.95 | 7.4% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.61 | 7.2% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $135.27 | 6.6% | 11 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $121.46 | 6.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.41 | 4.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.03 | 3.8% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $69.84 | 3.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.47 | 3.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.90 | 2.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.94 | 0.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.21 | 0.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.75 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,035.69 | 100 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $509.07 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $356.88 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $245.15 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $204.42 | 12 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $121.46 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $119.13 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $110.45 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $105.37 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $96.11 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $96.11 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.80 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $78.03 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $69.84 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.81 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.15 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $62.47 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.91 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.90 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.47 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.48 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.48 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.48 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.76 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $12.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 124 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 166 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 179 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
110 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
179 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 131 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 390 | 78 |
| Gabapentin | Gabapentin | 349 | 87 |
| Omeprazole | Omeprazole | 321 | 99 |
| Furosemide | Furosemide | 305 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 291 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 79 |
| Potassium Chloride | Potassium Chloride | 260 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 65 |
| Metformin Hcl | Metformin Hcl | 235 | 68 |
| Lisinopril | Lisinopril | 225 | 80 |
| Meloxicam | Meloxicam | 213 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 67 |
| Mounjaro | Tirzepatide | 179 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 40 |
| Losartan Potassium | Losartan Potassium | 173 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 60 |
| Jardiance | Empagliflozin | 166 | 36 |
| Alprazolam | Alprazolam | 163 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 43 |
| Ozempic | Semaglutide | 152 | 32 |
| Trazodone Hcl | Trazodone Hcl | 150 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 41 |
| Valsartan | Valsartan | 136 | 36 |
| Pregabalin | Pregabalin | 134 | 28 |
| Eliquis | Apixaban | 124 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 34 |
| Tramadol Hcl | Tramadol Hcl | 122 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 110 | 23 |
| Buspirone Hcl | Buspirone Hcl | 109 | 27 |
| Carvedilol | Carvedilol | 104 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 29 |
| Farxiga | Dapagliflozin Propanediol | 99 | 33 |
| Sertraline Hcl | Sertraline Hcl | 91 | 27 |
| Allopurinol | Allopurinol | 90 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 89 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 66 |
| Simvastatin | Simvastatin | 87 | 23 |
| Xarelto | Rivaroxaban | 80 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 22 |
| Azithromycin | Azithromycin | 78 | 62 |
| Clonazepam | Clonazepam | 76 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 22 |
| Celecoxib | Celecoxib | 74 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 16 |
| Lorazepam | Lorazepam | 70 | 21 |
| Estradiol | Estradiol | 69 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 17 |
| Famotidine | Famotidine | 59 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 16 |
| Prednisone | Prednisone | 59 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 44 |
| Alendronate Sodium | Alendronate Sodium | 53 | 17 |
| Chlorthalidone | Chlorthalidone | 52 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Spironolactone | Spironolactone | 49 | 16 |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Aripiprazole | Aripiprazole | 46 | 11 |
| Metformin Hcl Er | Metformin Hcl | 46 | 11 |
| Ondansetron Odt | Ondansetron | 45 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 16 |
| Promethazine Hcl | Promethazine Hcl | 45 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 11 |
| Montelukast Sodium | Montelukast Sodium | 40 | 14 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 39 | 20 |
| Ranolazine Er | Ranolazine | 39 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 13 |
| Fluconazole | Fluconazole | 36 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Sucralfate | Sucralfate | 35 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 13 |
| Baclofen | Baclofen | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 22 |
| Topiramate | Topiramate | 32 | 13 |
| Torsemide | Torsemide | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | 17 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Finasteride | Finasteride | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 12 |
| Mirtazapine | Mirtazapine | 23 | 12 |
| Naproxen | Naproxen | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Yaz | Ethinyl Estradiol/Drospirenone | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,035.69 · 100 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FLOWTRIEVER, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, PROQUAD, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VAXNEUVANCE, VIBERZI, VRAYLAR, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error